The Oncotype breast cancer test has been ordered in over 900,000 patients
If you have recently been diagnosed with early-stage oestrogen receptor positive (ER+) invasive breast cancer, you will discuss your treatment options with your doctor*. Choosing the optimal treatment for your breast cancer is important and you need to weigh the risks and benefits of chemotherapy with your doctor in order to make a decision that is right for you.
Applying Genomics to Cancer
A genomic test, such as the Oncotype DX test for invasive breast cancer, looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment. Unlike a breast cancer genetic test, the Oncotype DX breast cancer test does not provide information about a person’s inherited genetic make-up; instead it looks at genes in a patient’s breast tumour to understand how these genes interact and influence the tumour’s behaviour.
Because every woman’s tumor is unique, understanding the biology of your specific tumor will help you and your doctor make more confident decisions about your care. Find out if you’re eligible for the test.
About the Test
To date, the Oncotype breast cancer test has been ordered in over 900,000 patients. The Oncotype DX test can thus help you and your doctor to make a more informed and personalised decision about whether to treat with chemotherapy or not, based on further information that is specific to the biology of your cancer. The Oncotype DX test has been available in the UK and Ireland since the end of 2007, with usage in both the NHS and private sectors growing.
Learn More about the Oncotype DX Breast Recurrence Score Test »
* Breast surgeon or oncologist